Lilly Cuts Guidance on Disappointing Weight-Loss Drug Sales [Yahoo! Finance Canada]
Novo Nordisk A/S (NVO)
Last novo nordisk a/s earnings: 2/5 01:31 am
Check Earnings Report
US:NYSE Investor Relations:
novonordisk.com/investors.html
Company Research
Source: Yahoo! Finance Canada
Most Read from Bloomberg Listen to the Here's Why podcast on Apple, Spotify or anywhere you listen. The Indianapolis-based drugmaker now expects full-year sales of $45.4 to $46 billion, lowering the top end of earlier guidance from $46.6 billion. Lilly had raised its full-year guidance twice this year. Zepbound sales were $1.26 billion in the quarter, Lilly said in a statement, shy of the $1.63 billion expected on average by analysts. Revenue from all products was $11.4 billion, short of the $12.2 billion average estimate of analysts. Lilly said wholesalers had higher inventory of Zepbound and Mounjaro in the last quarter, which dragged on sales. The company's shares fell 8% in pre-market trading. Obesity is one of the largest and fastest-growing areas for the pharmaceutical industry, analysts estimate the market for weight-loss treatments will reach $130 billion by 2030. Lilly's success in the category has made it the most valuable drug company in the world. It compete
Show less
Read more
Impact Snapshot
Event Time:
NVO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NVO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NVO alerts
High impacting Novo Nordisk A/S news events
Weekly update
A roundup of the hottest topics
NVO
News
- Healthy Returns: Wegovy may reduce knee pain in patients with a type of arthritis and obesity [CNBC]CNBC
- Semaglutide linked to reduced arthritis knee pain in people with obesity, study finds [MSNBC.com]MSNBC.com
- Novo Nordisk's Ozempic and Wegovy now available in the U.S. after shortages, FDA says [CNBC]CNBC
- Lilly Cuts Guidance on Disappointing Weight-Loss Drug Sales [BNN Bloomberg (Canada)]BNN Bloomberg
- Lilly Cuts Guidance on Disappointing Weight-Loss Drug Sales [Yahoo! Finance]Yahoo! Finance
NVO
Earnings
- 8/8/24 - Beat
NVO
Sec Filings
- 10/28/24 - Form 6-K
- 10/21/24 - Form 6-K
- 10/21/24 - Form 6-K
- NVO's page on the SEC website